Effect of bezafibrate on HDL with apo A-I and apo A-II and on HDL with apo A-I without apo A-II hyperlipidaemic patients

A. Branchi, A. Rovellini, D. Sommariva

Research output: Contribution to journalArticle

Abstract

On the basis of apoprotein composition, high-density lipoprotein (HDL) particles may be subdivided into two main subpopulations defined by the presence in the lipoprotein molecule of apo A-I (Lp A-I) and of both apo A-I and apo A-II (Lp A-I:A-II). The effect of slow-release bezafibrate 400 mg a day on Lp A-I and Lp A-I:A-II was evaluated in 34 hyperlipidaemic patients (19 with hypercholesterolaemia and 15 with hypertriglyceridaemia). Seventeen patients on low-fat low-cholesterol diet only were taken as the reference group. In the reference group, no change in HDL-C, apo A-I, apo A-II, Lp A-I and Lp A-I:A-II occurred during the 3 months of observation. In patients on bezafibrate, HDL-C, apo A-I and apo A-II significantly increased. Lp A-I:A-II increased by 33% in hypercholesterolaemic and by 29% in hypertriglyceridaemic patients. Lp A-I decreased by 15% in hypercholesterolaemic patients and did not change significantly in hypertriglyceridaemic patients. This differential effect of bezafibrate on apo-A-defined HDL subpopulations in hypertriglyceridaemia and in hypercholesterolaemia is in accord with previous studies on the effect of the drug on HDL subfractions defined by their density.

Original languageEnglish
Pages (from-to)153-158
Number of pages6
JournalInternational Journal of Clinical Pharmacology Research
Volume15
Issue number4
Publication statusPublished - 1995

Fingerprint

Bezafibrate
Apolipoprotein A-II
Apolipoprotein A-I
HDL Lipoproteins
Lipoproteins
Hypertriglyceridemia
Hypercholesterolemia
Apolipoproteins A
Fat-Restricted Diet
Apoproteins

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{b90f9a23278e4bd1afbfbcf15609cc46,
title = "Effect of bezafibrate on HDL with apo A-I and apo A-II and on HDL with apo A-I without apo A-II hyperlipidaemic patients",
abstract = "On the basis of apoprotein composition, high-density lipoprotein (HDL) particles may be subdivided into two main subpopulations defined by the presence in the lipoprotein molecule of apo A-I (Lp A-I) and of both apo A-I and apo A-II (Lp A-I:A-II). The effect of slow-release bezafibrate 400 mg a day on Lp A-I and Lp A-I:A-II was evaluated in 34 hyperlipidaemic patients (19 with hypercholesterolaemia and 15 with hypertriglyceridaemia). Seventeen patients on low-fat low-cholesterol diet only were taken as the reference group. In the reference group, no change in HDL-C, apo A-I, apo A-II, Lp A-I and Lp A-I:A-II occurred during the 3 months of observation. In patients on bezafibrate, HDL-C, apo A-I and apo A-II significantly increased. Lp A-I:A-II increased by 33{\%} in hypercholesterolaemic and by 29{\%} in hypertriglyceridaemic patients. Lp A-I decreased by 15{\%} in hypercholesterolaemic patients and did not change significantly in hypertriglyceridaemic patients. This differential effect of bezafibrate on apo-A-defined HDL subpopulations in hypertriglyceridaemia and in hypercholesterolaemia is in accord with previous studies on the effect of the drug on HDL subfractions defined by their density.",
author = "A. Branchi and A. Rovellini and D. Sommariva",
year = "1995",
language = "English",
volume = "15",
pages = "153--158",
journal = "International Journal of Clinical Pharmacology Research",
issn = "0251-1649",
publisher = "Bioscience Ediprint Inc.",
number = "4",

}

TY - JOUR

T1 - Effect of bezafibrate on HDL with apo A-I and apo A-II and on HDL with apo A-I without apo A-II hyperlipidaemic patients

AU - Branchi, A.

AU - Rovellini, A.

AU - Sommariva, D.

PY - 1995

Y1 - 1995

N2 - On the basis of apoprotein composition, high-density lipoprotein (HDL) particles may be subdivided into two main subpopulations defined by the presence in the lipoprotein molecule of apo A-I (Lp A-I) and of both apo A-I and apo A-II (Lp A-I:A-II). The effect of slow-release bezafibrate 400 mg a day on Lp A-I and Lp A-I:A-II was evaluated in 34 hyperlipidaemic patients (19 with hypercholesterolaemia and 15 with hypertriglyceridaemia). Seventeen patients on low-fat low-cholesterol diet only were taken as the reference group. In the reference group, no change in HDL-C, apo A-I, apo A-II, Lp A-I and Lp A-I:A-II occurred during the 3 months of observation. In patients on bezafibrate, HDL-C, apo A-I and apo A-II significantly increased. Lp A-I:A-II increased by 33% in hypercholesterolaemic and by 29% in hypertriglyceridaemic patients. Lp A-I decreased by 15% in hypercholesterolaemic patients and did not change significantly in hypertriglyceridaemic patients. This differential effect of bezafibrate on apo-A-defined HDL subpopulations in hypertriglyceridaemia and in hypercholesterolaemia is in accord with previous studies on the effect of the drug on HDL subfractions defined by their density.

AB - On the basis of apoprotein composition, high-density lipoprotein (HDL) particles may be subdivided into two main subpopulations defined by the presence in the lipoprotein molecule of apo A-I (Lp A-I) and of both apo A-I and apo A-II (Lp A-I:A-II). The effect of slow-release bezafibrate 400 mg a day on Lp A-I and Lp A-I:A-II was evaluated in 34 hyperlipidaemic patients (19 with hypercholesterolaemia and 15 with hypertriglyceridaemia). Seventeen patients on low-fat low-cholesterol diet only were taken as the reference group. In the reference group, no change in HDL-C, apo A-I, apo A-II, Lp A-I and Lp A-I:A-II occurred during the 3 months of observation. In patients on bezafibrate, HDL-C, apo A-I and apo A-II significantly increased. Lp A-I:A-II increased by 33% in hypercholesterolaemic and by 29% in hypertriglyceridaemic patients. Lp A-I decreased by 15% in hypercholesterolaemic patients and did not change significantly in hypertriglyceridaemic patients. This differential effect of bezafibrate on apo-A-defined HDL subpopulations in hypertriglyceridaemia and in hypercholesterolaemia is in accord with previous studies on the effect of the drug on HDL subfractions defined by their density.

UR - http://www.scopus.com/inward/record.url?scp=0029585353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029585353&partnerID=8YFLogxK

M3 - Article

C2 - 8871265

AN - SCOPUS:0029585353

VL - 15

SP - 153

EP - 158

JO - International Journal of Clinical Pharmacology Research

JF - International Journal of Clinical Pharmacology Research

SN - 0251-1649

IS - 4

ER -